PD-L1单抗-话题@MedSci

#PD-L1单抗#

49篇内容 | 2480人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1538978, encodeId=854015389e828, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, objectType=article, longId=188787, objectId=ec53188e8791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec53188e8791, replyNumber=0, likeNumber=99, createdTime=2020-02-27, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec53188e8791, moduleTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec53188e8791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538977, encodeId=c1e915389e742, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=64, createdTime=2020-01-08, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538976, encodeId=487a15389e6b0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, objectType=article, longId=185527, objectId=8ca718552e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca718552e25, replyNumber=0, likeNumber=69, createdTime=2020-01-03, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca718552e25, moduleTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca718552e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538975, encodeId=b7cc15389e537, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, objectType=article, longId=184877, objectId=fe901848e7f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe901848e7f2, replyNumber=0, likeNumber=77, createdTime=2019-12-19, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe901848e7f2, moduleTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe901848e7f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538974, encodeId=95a515389e46c, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=66, createdTime=2019-12-08, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538973, encodeId=ec7015389e32d, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, objectType=article, longId=183990, objectId=e516183990ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e516183990ae, replyNumber=0, likeNumber=60, createdTime=2019-12-04, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e516183990ae, moduleTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e516183990ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538972, encodeId=3e0915389e221, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=70, createdTime=2019-11-26, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538971, encodeId=f56215389e18d, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=77, createdTime=2019-10-24, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538970, encodeId=cd2115389e010, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, objectType=article, longId=180569, objectId=13a6180569e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a6180569e0, replyNumber=0, likeNumber=66, createdTime=2019-10-07, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a6180569e0, moduleTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a6180569e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538969, encodeId=2efd1538969aa, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, objectType=article, longId=180568, objectId=34561805686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34561805686b, replyNumber=0, likeNumber=66, createdTime=2019-10-07, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34561805686b, moduleTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34561805686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538968, encodeId=35d2153896896, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, objectType=article, longId=180564, objectId=58f6180564c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f6180564c6, replyNumber=0, likeNumber=68, createdTime=2019-10-07, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f6180564c6, moduleTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f6180564c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538967, encodeId=3878153896e5d, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=38, createdTime=2019-09-29, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538966, encodeId=bc6515389662d, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=中国首部PD-1/PD-L1单抗使用后导致的肺炎诊疗共识重磅发布！ | 2019 CTS, objectType=article, longId=179124, objectId=69531e9124ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69531e9124ad, replyNumber=0, likeNumber=85, createdTime=2019-09-10, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69531e9124ad, moduleTitle=中国首部PD-1/PD-L1单抗使用后导致的肺炎诊疗共识重磅发布！ | 2019 CTS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69531e9124ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538965, encodeId=afd21538965c4, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, objectType=article, longId=178551, objectId=036a1e8551e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=036a1e8551e1, replyNumber=0, likeNumber=59, createdTime=2019-09-03, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=036a1e8551e1, moduleTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=036a1e8551e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538964, encodeId=8912153896489, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, objectType=article, longId=177619, objectId=7d301e761945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d301e761945, replyNumber=0, likeNumber=0, createdTime=2019-08-16, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d301e761945, moduleTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d301e761945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538963, encodeId=556615389636c, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, objectType=article, longId=177126, objectId=a2121e71269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2121e71269e, replyNumber=0, likeNumber=73, createdTime=2019-08-09, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2121e71269e, moduleTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2121e71269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538962, encodeId=3bda15389621a, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, objectType=article, longId=175359, objectId=a0671e535994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0671e535994, replyNumber=0, likeNumber=80, createdTime=2019-07-14, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0671e535994, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0671e535994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538961, encodeId=0f1b1538961c0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=70, createdTime=2019-06-29, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538960, encodeId=0b441538960fc, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效, objectType=article, longId=168072, objectId=0b361680e285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b361680e285, replyNumber=0, likeNumber=67, createdTime=2019-06-12, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b361680e285, moduleTitle=基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b361680e285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538959, encodeId=53c31538959d7, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, objectType=article, longId=166173, objectId=9b091661e313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b091661e313, replyNumber=0, likeNumber=72, createdTime=2019-05-17, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b091661e313, moduleTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b091661e313)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1单抗

2020-05-29

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq在美国获得优先审查

2020-02-27

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

2020-01-03

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险

2019-12-19

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2019-12-08

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查

2019-12-04

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2019-11-26

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效

2019-10-07

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期

2019-10-07

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say

2019-10-07

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-09-29

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

中国首部PD-1/PD-L1单抗使用后导致的肺炎诊疗共识重磅发布！ | 2019 CTS

2019-09-10

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌

2019-09-03

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法

2019-08-16

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人

2019-08-09

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定

2019-07-14

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效

2019-06-12

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌

2019-05-17

科室
- - 订阅+
  - 更多科室
工具
服务